key: cord-0071765-vtvbxo5v
authors: nan
title: 2021 Annual World Congress of the Pulmonary Vascular Research Institute Webinar Series
date: 2021-12-14
journal: Pulm Circ
DOI: 10.1177/20458940211053994
sha: dfdebd064827c9d8cb4e21a8da80f63fc0a4b472
doc_id: 71765
cord_uid: vtvbxo5v

nan

failure. Conclusions: our center has a cohort of patients with triple therapy, which, although based on the European PAH guidelines, is adjusted to the accessibility of medications. They are young women, with more common idiopathic PAH, with FC III and five-year survival of 76%, comparable with other international reports due to the severity of the disease. We did not find significant differences in morbidity and mortality events with different etiologies.

0003. Biomarker analysis of the PULSAR study: an ongoing phase 2, double-blind, placebo-controlled, randomized study to compare the efficacy and safety of sotatercept (ACE-011) versus placebo when added to standard of care for the treatment of pulmonary arterial hypertension (PAH) Disruptions in transforming growth factor (TGF)-b and bone morphogenetic protein (BMP) signaling are associated with PAH. BMP receptor type II gene (BMPR2) mutations underlie the majority of familial PAH cases; however, the relevance of the BMPR-II pathway extends beyond familial PAH. Sotatercept, a first-in-class fusion protein, binds select TGF-b superfamily ligands to suppress TGF-b signaling and rebalance BMPR-II signaling. PULSAR (NCT03496207) released positive topline results this year. One hundred and six patients enrolled: Group 1 PAH; functional classes II-III; age !18; pulmonary vascular resistance (PVR) !5 Wood units, on stable PAH standard of care (SOC) therapy (all combinations allowed). Study drug was administered by subcutaneous injection every 21 days for a 24-week double-blind, placebo-controlled treatment period in three arms: placebo þ SOC, 0.3 mg/kg sotatercept þ SOC, 0.7 mg/kg sotatercept þ SOC. 24-week endpoints included PVR, 6MWD, NT-proBNP. Biomarkers were assessed at baseline and during treatment: NT-proBNP, TGF-b1, activin A, GDF15, VEGFR1, FSH, estradiol, testosterone, and BMPR2 mRNA expression. Sequence variation of ACVRL1, BMPR2, CAV1, EIF2AK4, ENG, KCNA5, KCNK3, SMAD9 was assessed at baseline. During the treatment period, NT-proBNP and activin A decreased rapidly in both sotatercept arms compared to placebo; no differences observed in the other biomarkers. BMPR2 mRNA expression was similar over time in all groups. Of 94 patients with reportable baseline genetic results, 68.1% had no variations, 26.6% had !one BMPR2 variation, and 5.3% had !one variation in another gene. Change from baseline in PVR, 6MWD, or NT-proBNP was similar regardless of BMPR2 mutation. Sotatercept induces change in activin A and NT-proBNP expression, consistent with its observed clinical efficacy in PULSAR and proposed mechanism of action. Of note, the treatment effect of sotatercept was observed independent of BMPR2 status, and sotatercept treatment did not affect BMPR2 mRNA expression. These results provide further evidence of sotatercept's potential role in the treatment of PAH.

Pulmonary arterial hypertension (PAH) treatment guidelines recommend patients achieve/maintain a low-risk profile. Many patients treated with PAH-targeted therapy do not meet this treatment goal. The aim of this study is to compare switching to riociguat (RIO) with continued phosphodiesterase type 5 inhibitors (PDE5i) in intermediate-risk patients with PAH. REPLACE (NCT02891850) was a randomized, open-label, 24-week Phase 4 study. Patients in WHO functional class (FC) III, with 6-minute walking distance (6MWD) 165-440 m were randomized to remain on PDE5i or switch to RIO 2.5 mg tid-max. Endothelin receptor antagonist pretreatment continued in both arms. The blinded, centrally adjudicated composite primary endpoint was defined as no clinical worsening (death from any cause, hospitalization for worsening PAH or disease progression) plus clinical improvement (two of the following: !10%/!30 m increase in 6MWD, WHO FC I/II, or !30% reduction in N-terminal pro-brain natriuretic peptide (NT-proBNP)). Secondary endpoints included 6MWD, WHO FC (both blinded assessments), NT-proBNP, and clinical worsening. Safety was evaluated throughout. One hundred and eleven patients were randomized to RIO, 115 to PDE5i. The primary endpoint was met in 45 patients (41%) treated with RIO and 23 (20%) treated with PDE5i (odds ratio (OR) 2.8; 95% confidence interval (CI) 1.5-5.1; p ¼ 0.0007). Of those not achieving the endpoint, one patient treated with RIO (1%) and 10 patients treated with PDE5i (9%) had clinical worsening (OR 0.10; 95% CI 0.01-0.73; p ¼ 0.0047) including three patients treated with PDE5i (3%) who died. There were no deaths in the RIO arm. AEs were similar between arms, with a higher incidence of serious AEs with PDE5i (17%) than RIO (7%). In conclusion, REPLACE demonstrated that patients on PDE5i at intermediate risk are more likely to show clinical improvement without clinical worsening upon switching to RIO than those who remain on PDE5i. Disclosures: The REPLACE Study was co-funded by Bayer AG (Berlin, Germany) and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA) . RL Benza reports grants from Actelion, Belleraphon, Bayer AG, and EIGER. 0005. A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach Pulmonary arterial hypertension (PAH) is a rare but lifeshortening disease, the diagnosis of which is often delayed, and requires an invasive right heart catheterisation. Identifying diagnostic biomarkers may improve screening to identify patients at risk of PAH earlier. MicroRNAs are small, noncoding molecules of RNA circulating miRNAs have been shown to be dysregulated in PAH, and contribute to the disease process in animal models. Diagnostic panels of microRNAs have had utility in other diseases, and there is scope to utilise multiple machine learning approaches for defining a diagnostic panel for PAH. Plasma from 64 treatment-naïve patients with PAH and 43 disease and healthy controls were profiled for microRNA expression by Agilent Microarray. Following quality control, analysis of variance and normalisation, the cohort was split into a training and validation set. The training set was then used to create a test panel. Four separate machine learning feature selection methods (Boruta, XGBoost, Lasso and Rpart) were applied. Twenty microRNAs were identified as relevant by consensus feature selection from all four methods and compared with univariate analysis to select potential biomarkers. Two consensus microRNAs (miR-636 and miR-187-5p) were selected by all methods and used to predict PAH diagnosis with high accuracy. Integrating microRNA expression profiles with their associated target mRNA revealed that gene targets in a classification model produced a 95% CI AUC 0.72-0.91 in a separate RNA dataset. In conclusion, this consensus of multiple machine learning approaches identified two consensus miRNAs that were able to classify PAH from disease and healthy controls. These circulating miRNA, and their target genes may provide a novel PAH signature, reveal novel regulators of disease and putative drug targets.

0006. Tricuspid regurgitation, as proxy for acute pulmonary hypertension, and its association with short-term outcome in severe C. Frostell 1 , J. Norderfeldt 2 , M. Eriksson 2 , A. Liliequist 3 , E. Weitzberg 4 , C. Adding 5 , P. Agvald 4 and P.-A. L€ onnqvist 4 Critically ill Covid-19 patients are likely to develop the sequence of acute pulmonary hypertension (aPH), right ventricular strain (RVS), and eventually failure due to currently known pathophysiology (endothelial inflammation plus thromboembolism) (1,2) that promotes increased pulmonary vascular resistance and pulmonary artery pressure. Although case reports of acute cor pulmonale exist (3), there is still no information on how frequently aPH and/or RVS is associated with severe Covid-19 and whether it affects outcome. Following approval from the National Ethics Committee, the medical records of 50 consecutive Covid-19 ICU patients during one month were reviewed. All trans-thoracic echocardiography examinations (TTE) were performed by the same experienced echocardiographer per established TTE guidelines (4,5). A tricuspid regurgitation (TR), large enough to allow the assessment of systolic pulmonary artery pressure (sPAP), was chosen as a marker of aPH and RVS. Plasma NTproBNP and plasma D-dimer (same day as the TTE examination) were used as biomarkers of cardiac failure and degree of thromboembolism, respectively. Short-term outcome (mortality at 21-days post-TTE) was also assessed. Twenty-six (52%) patients displayed a measurable TR (group TRm), whereas 24 (48%) did not (group nTR). Left ventricular ejection fraction was similar in both groups (Mann-Whitney; p ¼ 0.4827) as were D-dimer (p ¼ 0.3363). NTproBNP was significantly higher in group TRm, p ¼ 0.0011. Twenty-one-day mortality was significantly higher in group mTR (10/26; 38.5%) compared to group nTR (2/24; 8.3%) (Chi square with Yates correction: p < 0.05). In conclusion, the presence of a measurable TR (proxy for acute pulmonary hypertension and/or right ventricular strain) was common in severely ill Covid-19 patients and was linked to biomarker-defined cardiac failure. Furthermore, the presence of a measurable TR was associated with increased short-term mortality. The prevalence of venous (VTE) and arterial (ATE) thromboembolism in patients with COVID-19 remains largely unknown. In this meta-analysis, we systematically searched for observational studies describing the prevalence of VTE and ATE in COVID-19 from 1 January to 30 September 2020. We identified 102 studies (28,684 patients). The frequency of COVID-19-related VTE was 14.8% (95%CI 12.1-17.7%, I 2 ¼ 94%, 56 studies; 16,481 patients). The overall prevalence of pulmonary embolism (PE) and leg deep vein thrombosis (DVT) were 7.8% (95%CI 6.2-9.4%, I 2 ¼ 94%; 66 studies; 23,117 patients) and 11.2% (95%CI 8.4-14.3%; I 2 ¼ 95%; 48 studies; 13,824 patients), respectively. The VTE prevalence was significantly higher in ICU (23.2%; 95%CI 17.5-29.6%; I 2 ¼ 92% vs. 9.0%; 95%CI 6.9-11.4%; I 2 ¼ 95%; p interaction < 0.01) and in series systematically screening patients compared to series testing symptomatic patients (25.2% vs. 12.7%, p interaction ¼ 0.04). The frequency of overall ATE, acute coronary syndrome, stroke, and other ATE was 3.9% (95%CI 2.0-6.5%, I 2 ¼ 96%; 19 studies; 8,249 patients), 1.1% (95%CI 0.2-3.0%, I 2 ¼ 96%; 16 studies; 7,939 patients), 1.6% (95%CI 1.0-2.2%, I 2 ¼ 93%; 27 studies; 40,597 patients), and 0.9% (95%CI 0.5-1.5%; I 2 ¼ 84%; 17 studies; 20,139 patients), respectively. Meta-regression and subgroup analyses failed to explain heterogeneity of overall ATE. High heterogeneity limited the value of estimates. In conclusion, the prevalence of VTE is significant amongst patients hospitalized for COVID-19, especially when admitted in the ICU with high D-dimers levels. Further studies are needed to determine the best management strategies. 0008. Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin Iona Cuthbertson, Paola Caruso and Nicholas Morrell Department of Medicine, University of Cambridge, Cambridge, UK Pulmonary arterial hypertension (PAH) is an often-fatal disease, characterised by the development of apoptosis-resistant, hyperproliferative, and hyper-glycolytic endothelial cells (ECs), and elevated expression of pyruvate kinase M2 isoform (PKM2) and poly-pyrimidine tract-binding protein (PTBP1)1. The flavone apigenin has been recognised for its ability to suppress PTBP1 and PKM2-driven warburg glycolysis and tumorigenesis 2. Whether apigenin influences PTBP1/PKM2 expression, metabolism and function in ECs is not known. Here, we examined the metabolic, genetic and proteomic profiles of blood outgrowth endothelial cells (BOECs) obtained from healthy volunteers and PAH patients with BMPR2 mutations, following apigenin treatment or PTBP1/PKM2 knockdown. We hypothesised that, in healthy and BMPR2 mutant BOECs, apigenin treatment would reduce glycolysis by inhibiting PTBP1-driven splicing of PKM into PKM2, and PKM2-dependent expression of glycolytic pathway components. We also questioned whether apigenin treatment is able to normalise EC metabolism and function. In control and BMPR2 mutant BOECs, apigenin strongly reduced PTBP1 expression. Apigenin only marginally suppressed HNRNPA2 and PKM2 expression, suggesting HNRNPA2 may compensate for the loss of PTBP1 to maintain PKM2 expression in ECs. Whether apigenin influences PKM2 isoform expression and localisation remains to be confirmed. In control BOECs, apigenin suppressed lactate production, LDHA mRNA and protein expression, and reduced LDHA expression in BMPR2 mutant BOECs. In addition, apigenin appeared to marginally suppress PKM1 and PKM2 expression. Apigenin also inhibited PUMA expression, and caspase 3/7 activity in both control and BMPR2 mutant cells, with similar results observed following knockdown of PTBP1 or PKM2. Taken together, these data suggest apigenin may induce downregulation of the glycolytic proteome, as well as suppressing PKM2/ PTBP1 driven apoptosis. In conclusion, apigenin treatment inhibits PTBP1 expression, glycolytic output, and apoptosis in healthy and BMPR2 mutant ECs. This encouraging data suggests that apigenin may be an effective treatment for endothelial cell dysfunction in PAH.

Evidence of epigenome-wide alterations that facilitates normal vascular cells to acquire and exhibit pro-proliferative, apoptotic-resistant, pro-inflammatory phenotypes in pulmonary arterial hypertension (PAH) remains unexplored at a genome-wide scale. Our major objectives were to (1) employ multiple nextgeneration sequencing (NGS) approaches to profile vascular cell-specific epigenomic alterations in human setting, (2) identify gene regulatory signatures, (3) identify transcription factor networks associated with hypertensive phenotypes, (4) evaluate the therapeutic potential of epigenetic intervention. Cellspecific transcriptome profiling revealed differential expression of 2069 genes (two-fold) in ex vivo isolated pulmonary artery adventitial fibroblasts (PAFBs) from idiopathic PAH (IPAH) and human donors, which strongly indicated the existence of genome-scale alterations in transcription regulatory mechanisms of PAH. To map the PAH-associated epigenomic alterations in the chromatin landscape of PAH vascular cells, we employed ChIP-seq to generate genome-wide maps for RNA polymerase II occupancy, histone modifications associated with euchromatin (H3K9/K14ac, H3K4me3, pan-H4Kac), heterochromatin (H3K27me3, H3K9me3) and enhancers (H3K27ac, H3K4me1). Bioinformatic analysis confirmed massive epigenetic alterations in both histone acetylation and methylation pattern in IPAH, which corroborated with aberrant expression and recruitment of histone-modifying enzymes in IPAH. KEGG analysis of epigenetic signatures revealed association with ABC transporters, smooth muscle contraction, cGMP-PKG, renin secretion, NF-jB, TGFb and cancer-signaling pathways. Integrative analysis also revealed acquisition of pro-hypertensive gene expression signatures in PAH, that includes differential regulation of novel transcription factor networks (SOX, ID, HES, GLI, GATA, REL) that may altogether coordinate the pro-proliferative and pro-inflammatory phenotypes in PAH. Aberrant epigenetic signatures in PAH were reversed by targeting chromatin-modifying enzymes ex vivo and in vivo. In conclusion, integrative analysis of vascular cellspecific epigenomics data confirmed genome-scale alterations in the chromatin landscape and DNA accessibility leading to aberrant transcriptional responses in PAH. This genome-scale study also uncovered novel regulatory factors, signaling networks and potential targets for therapeutic intervention.

0010. Implication of the histone methyltransferase "G9a" in pulmonary arterial hypertension Pulmonary arterial hypertension (PAH) is a rare, but lethal vascular disease characterized by a mean resting pulmonary artery (PA) pressure that exceeds 20 mmHg. Pulmonary artery smooth muscle cells (PASMCs) from PAH patients exhibit a cancer-like hyperproliferative and apoptosis-resistant phenotypes leading to pulmonary vascular remodeling. It is believed that these alterations are influenced by epigenetic processes. However, it is still not clear which gene are the drivers. For instance, "G9a," a histone methyltransferase, has been observed to be overexpressed in different types of cancer. Given the similarities between PAH and cancer, we hypothesized that G9a could be implicated in PAH pathogenesis. Using Western blot (WB) and immunofluorescence (IF), we demonstrated that G9a is significantly overexpressed in distal PAs and PASMCs from PAH patients (p < 0.01). Similarly, G9a was increased (p < 0.05) in two PAH animal models; namely, the monocrotaline rat and mice exposed to chronic hypoxia. In vitro, we found that G9a pharmacological inhibition using BIX01294 reduces PAH-PASMC proliferation (Ki67 and Edu assays, p < 0.001) and survival (Annexin V assay p < 0.001). Through RNA sequencing analysis conducted in PAH-PASMCs treated or not with BIX01294, we found that upregulated genes were significantly enriched in "cholesterol biosynthesis," "apoptotic positive regulation" and "autophagy." Consistently, G9a inhibition was accompanied by an increased lipid accumulation (Oil red staining) and an impaired autophagy flux as evidenced by the appearance of numerous cytoplasmic vacuoles positive for LC3-II (IF, WB), an increased p62 expression (WB), the accumulation of merged yellow puncta in PAH-PASMCs expressing the RFP-GFP-LC3 fusion protein and the unaffected LC3-II expression after adding chloroquine, an autophagic flux inhibitor. In conclusion, we showed for the first time that G9a is overexpressed in human and experimental PAH contributing to the pro-proliferative and anti-apoptotic phenotype of PAH. Current experiments aim to determine whether G9a pharmacological inhibition provides therapeutic benefits in vivo. Perinatal time is a critical period of development of the pulmonary vessels. Stimuli acting at this time have more permanent effects than the same stimuli acting at other life periods. Females are more susceptible to this effect. Pulmonary hypertension is a group of disorders with poor prognosis. While its mechanisms are multifactorial, one component involves serotonin (5-HT) signaling. Pulmonary endothelial 5-HT synthesis is increased in pulmonary hypertension. Inhibition of the 5-HT1B receptors reduces pulmonary hypertension. Because 5-HT reuptake inhibitors represent the key medication for treating depressive disorders and their use during pregnancy is common (3), we decided to study the long-term consequences of maternal ingestion of selective 5-HT re-uptake inhibitor (SSRI; fluoxetine, 0.2 g/l in drinking water) on adult offspring and to compare them with the known effects of perinatal hypoxia. We found that mean pulmonary artery pressure (mPAP) was significantly elevated (P < 0.05) in adult females that experienced hypoxia in the perinatal period (21.8 AE 2.0 mmHg) compared to adult females that have never experienced hypoxia (15.4 AE 0.9 mmHg), confirming our previous findings. When perinatally normoxic females were exposed in utero to fluoxetine, their mPAP in adulthood was similarly increased (to 21.8 AE 2.3 mmHg) as in the adult females exposed to perinatal hypoxia. Male adults did not exhibit this effect (mPAP 17.9 AE 1.1 in controls vs. 14.9 AE 1.3 mmHg after maternal fluoxetine, P>0.05). We conclude that in rats, maternal ingestion of fluoxetine (and possibly other SSRIs) has a long-lasting effect on mPAP in their female (but not male) offspring.

Anandharajan Rathinasabapathy, Christy Moore, Santhi Gladson, Sheila Shay, Anna Dikalova and James West

Vanderbilt University Medical Center, Nashville, TN, USA Growing evidence and our previous finding suggest that metabolic perturbation is one of the etiological factors driving idiopathic and hereditary pulmonary arterial hypertension (PAH). We and others have demonstrated that loss of Sirt3 function is one of the major factors driving IPAH and HPAH. However, the endothelial-specific role of Sirt3 in rescuing PAH in the context of deacetylation of its downstream targets is unknown. In this study, we have used sugen-hypoxia insult on wild-type and Sirt3 OE (endothelial specific Sirt3 overexpression) animals. We also have used human lung microvascular endothelial cells (LMVECs) from control and HPAH subjects to investigate the vascular leak. Molecular characterization experiments such as morphometric staining, immunoprecipitation and Western blots were performed on in vivo lung tissues, investigating the downstream targets of Sirt3. Our in vivo study demonstrated that endothelial-specific overexpression of Sirt3 (Sirt3 OE ) reduced the development of PAH in sugen-hypoxia (Su-Hyx) animals. Molecular characterization demonstrated that mitochondrial Sirt3 targets -ATP5a, LCAD and IDH2 have little change in protein levels; however, they are significantly acetylated at the lysine residue, which would be expected to reduce function. In addition, we saw downregulation of targets of b-oxidation (CPT1) and vascular leak (Occludin). All these molecular abnormalities were rescued by Sirt3 OE animals. Our ECIS study on LMVECs demonstrated a significant vascular permeability in PAH. Further, morphometric staining on BMPR2 PAH lung tissue (In vivo) and Western blot analysis of LMVECs, Su-Hyx lung tissues and patient-derived blood cells demonstrated that malfunction of SOD2 through its acetylation contribute to the etiology of PAH. In conclusion, in this pilot study, we have demonstrated that loss of function of Sirt3 targets, specifically through their lysine acetylation contributes to PAH etiology. We have also identified that these metabolic abnormalities are associated with the dysregulation of endothelial integrity. Pulmonary arterial hypertension (PAH) is a fatal disease characterized by a pseudo-malignant phenotype. Previous reports indicate that a member of the TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs), Axl controls cancer progression and metastasis. We investigated the expression and the role of the receptor tyrosine kinase Axl in experimental (i.e. monocrotaline and Su5416/ hypoxia treated rats) and clinical PAH. Axl expression was augmented in experimental PH. Axl inhibition by R428 and Axl knockdown inhibited growth factor-driven proliferation and migration of non-PAH and PAH PASMCs in vitro. Conversely, Axl overexpression in PASMCs conferred a growth advantage. R428 aggravated right ventricular hypertrophy and dysfunction, abrogated bone morphogenetic protein (BMP) receptor 2 (BMPR2) signaling, augmented pro-inflammatory response, elevated pulmonary endothelial cell apoptosis and loss, affecting pulmonary vascular remodeling. Axl inhibitor led to alterations of endothelial cell permeability and endothelial cell cytotoxicity and death in vitro. Axl expression declined in blood outgrowth endothelial cells (BOECs), in laser-assisted microdissected intrapulmonary vessels and in the pulmonary endothelium of IPAH patients. Axl blockage by R428 inhibited BMP signaling and increased PAEC apoptosis, while BMP9 induced Axl phosphorylation in a time-dependent manner. Outstandingly, Axl ligand Gas6-induced SMAD1/5/8 phosphorylation and ID1/ID2 increase were both blunted by BMP signaling obstruction. Furthermore, Axl knockdown diminished BMP9induced signaling in hPAECs at the level of ID1, ID2, and E-selectin mRNA expression. Proximity-ligation assays and immunoprecipitations revealed that Axl and BMPR2 co-interacted in hPAECs, signifying a previously unrecognized association between these two receptors. Axl association with BMPR2 was facilitated by Gas6/BMP9 stimulation and diminished by R428. In conclusion, Axl is a key regulator of endothelial BMPR2 signaling and potential determinant of PAH. Paediatric pulmonary arterial hypertension (PAH) is a rare disease but causes significant morbidity and mortality. Literature on survival is scant. Data were extracted from the Pulmonary Hypertension Society of Australia and New Zealand registry for all patients with a diagnosis of idiopathic (iPAH) or heritable pulmonary arterial hypertension (hPAH), diagnosed between three months of age and less than 21 years. Analysis was performed in Jupyterlab. One hundred patients were diagnosed with iPAH or hPAH between 1988 and 2019 in the registry and had survival data available. Compared to hPAH patients, iPAH patients had worse right atrial pressure and cardiac index at baseline, despite similar mean pulmonary pressures, suggestive of worse right ventricular function. Functional status was also worse and iPAH patients were diagnosed at a younger age. Our data show transplant-free survival in hPAH patients compared with iPAH, with no significant difference between the curves (log rank test p ¼ 0.13). An analysis of mortality-only also showed no significant difference but suggested a trend towards improved survival in hPAH patients, with a log rank test p ¼ 0.06. In conclusion, heritable PAH paediatric patients were diagnosed with better functional class and better haemodynamic measures of right ventricular function compared to idiopathic PAH. Despite this, survival was comparable between heritable and idiopathic PAH. Contrasting with adults, where hPAH is associated with worse outcomes, iPAH presenting in childhood is an equally severe disease, accounting for similar outcomes between these two groups.

Richard Channick 1 , Sarah Medrek 2 , Marion Delcroix 3 , Pavel Jansa 4 , Sanjay Mehta 5 , Tomas Pulido 6 , Bhaqavaula Sastry 7 , Rogerio Souza 8 , Adam Torbicki 9 , Carol Zhao 10 , Peter Agron 10 and Olivier Sitbon 11 In PAH, patient characteristics vary with age. Younger patients can have preserved functional capacity despite poor hemodynamics; geriatric patients can have poor outcomes due to comorbidities. This post-hoc analysis of SERAPHIN and GRIPHON identified prognostic age groups and determined macitentan treatment effect by age. SERAPHIN and GRIPHON were placebo-controlled trials evaluating macitentan and selexipag, respectively, with a time to morbidity/mortality event (M/M) primary endpoint. The placebo arms were used to define age thresholds differentiating M/M risk, using Cstatistics, receiver operator characteristics, and hazard ratio (HR) point estimates. Cox regression models adjusted for functional class, PAH background therapy, region, PAH etiology, sex, and race/ethnicity were used to determine the macitentan 10 mg treatment effect in SERAPHIN by age group. The risk of M/M was higher in younger and older patients with three age thresholds identified: < 35, 35-64, and !65 years. In the SERAPHIN placebo arm (n ¼ 250), patients < 35 had a 73% greater risk of M/M than those 35-64 (HR ¼ 1.73, 95% CI 1.10-2.72) and patients !65 had a 55% greater risk (HR ¼ 1.55, 95% CI 0.89-2.69). In the GRIPHON placebo arm (n ¼ 582), patients < 35 had an 82% greater risk of M/M than those 35-64 (HR ¼ 1.82, 95% CI 1.29-2.57) and patients !65 had a 7% greater risk (HR ¼ 1.07, 95% CI 0.75-1.54). Macitentan reduced the risk of M/M versus placebo in all age groups, with greatest reduction in the younger and middle-aged patients: < 35 (HR ¼ 0.44; 95% CI: 0.25-0.78); 35-64 (HR ¼ 0.50; 95% CI: 0.33-0.76); !65 (HR ¼ 0.69; 95% CI: 0.30-1.58). Incidence of AEs leading to macitentan discontinuation was similar across age groups. In conclusion, this analysis identified age < 35 as a risk factor and confirmed the prognostic significance of age !65. Patients in all age groups had a robust response to macitentan 10 mg. Studies showed that pulmonary vascular disease has a different effect on arteries and veins. We have recently proposed a method based on artificial intelligence that automatically separates the lung arterial and venous vasculature on non-contrast chest CT images. The purpose of this analysis was to validate of our approach on CT pulmonary angiography (CTPA) scans, which introduces the effects of contrast, in a PH population. The artery/vein classification followed two main steps. First, a scale-space particle approach was used to extract the intraparenchymal pulmonary vasculature. Then, a 3D convolutional neural network followed by graph-cuts (GC) optimization to disambiguate the two vascular trees was trained with manually annotated trees from non-contrast CT scans. Validation of the technique was performed by comparing our automatic approach against manually labeled vascular trees in the right lung of 62 subjects without and with PH (Groups 1, 2 and 4) for which CTPA scans were available. Manual labeling involved tracing the origin of the vessels to the main pulmonary artery and left atrium. Classification sensitivity (TPR), specificity (TNR), positive predictive value (PPV) and negative predicted value (NPV) were measured, where arteries and veins were the positive and negative class, respectively. Metrics were also stratified by lobe and vessel size (small, medium and large). Linear mixed effect models were used to assess difference across groups. Our data show the aggregated results by PH group. The overall specificity and sensitivity for the arteryvein classification were 95.64 AE 2.1% and 83.31 AE 10.98%, respectively. TPR was higher than TNR, while PPV was smaller than NPV across groups. Disease group was significant effect for TNR, PPV and NPV (p < 0.001) but not TPR when considering lobe and vessel size random effects. Lobe but not vessel size was a significant effect for TNR, PPV and NPV when disease group was considered a random effect. In this work, we have demonstrated that artificial intelligence is effective and highly accurate for artery-vein classification in CT images with contrast when compared to manually annotated scans.

The method is robust and shows very good performance with a moderate drop in performance by PH status with respect to controls likely due to the presence of parenchymal abnormalities in the disease group. Lobe but not vessel size was associated with differences in performance characteristics. Results are also likely to improve with specific training of the neural network on CTPA scans from PH subjects. Automated arterial-venous metrics of vascular remodeling may be used in clinical investigations without systematic differences in comparison to manually annotated scans. INCREASE was a 16-week trial evaluating the safety and efficacy of inhaled treprostinil (iTRE) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study met its primary efficacy endpoint of change in 6MWD, demonstrated by a 31 m improvement from baseline (260 m). Secondary endpoints, including change in NT-proBNP and time to clinical worsening, were also met. Post-hoc analyses were conducted to investigate clinical endpoints within patient subgroups. Patient subgroups were delineated by median values of the following baseline characteristics: PVR (<5 WU, !5 WU), PCWP (<10 mmHg, !10 mmHg), mPAP (<35 mmHg, !35 mmHg), DLCO (<27% predicted, !27% predicted), FVC (<60% predicted, !60% predicted) and NT-proBNP (<504 pg/mL, !504 pg/mL). Clinical worsening was defined as any of the following: cardiopulmonary hospitalization, decrease in 6MWD >15% from baseline, all-cause death, or lung transplantation. All 326 patients randomized in INCREASE were included in the present analyses. 6MWD improvements were demonstrated in all subgroups. Statistically significant improvements occurred in patients with above median PVR, PCWP, mPAP; lower than median DLCO; and in both above median and below median FVC and NT-proBNP cohorts (p 0.013 for all). Statistically significant reductions in NT-proBNP were demonstrated in all subgroups (p 0.028 for all). Statistically significant benefit in time to clinical worsening with iTRE was observed in above median PVR, mPAP, and NT-proBNP; and lower PCWP (p 0.0493 for all). Overall, response separation in clinical endpoints indicated greater improvement for patients with above median NT-proBNP and PVR. A similar trend of benefit was observed in lower DLCO and higher mPAP subgroups. In conclusion, these analyses demonstrate improvements in clinical endpoints with inhaled treprostinil across patient subgroups. Patients with more advanced pulmonary vascular disease stand to gain the most benefit with inhaled treprostinil therapy.

Acetazolamide inhibits hypoxic pulmonary vasoconstriction in humans and might prevent high altitude pulmonary edema (HAPE). We tested this hypothesis in a prospective, randomized, placebo-controlled, double-blind study in 13 nonacclimatized subjects with a history of HAPE at 4559 m. They rapidly ascended (<22 h) from 1130 m to 4559 m (Margherita Hut, Italy), with an overnight stay at 3611 m. Treatment started 48 h before ascent (acetazolamide: n ¼ 7, 250 mg 3Â/d; placebo: n ¼ 6, 3Â/d). HAPE was diagnosed by chest radiography taken at 423 m and then daily at high altitude. At low altitude and twice daily for three days, right ventricular-atrial pressure gradient (RVPG) was assessed by echocardiography, and peripheral oxygen saturation (SpO 2 ) were measured. Acute mountain sickness (AMS) was evaluated with the Lake Louise (LLS) and AMS-C scores. Acetazolamide reduced the incidence of HAPE from 67% to 43%, but this was not statistically significant (p ¼ 0.333). Ascent to 4559 m increased RVPG from 20 AE 5 to 43 AE 10 mmHg (p < 0.01) without a group difference (p ¼ 0.72). SpO 2 fell from 97 AE 1% to 71 AE 10% (p < 0.01) and was higher with acetazolamide at altitude (p ¼ 0.06). At first evaluation after ascent, LLS and AMS-C scores were 5.0 AE 1.9 and 0.58 AE 0.50 vs. 10.2 AE 4.8 and 1.78 AE 1.05 (acetazolamide vs. placebo, both p ¼ 0.01), and they remained lower with acetazolamide over the next two days. Although acetazolamide reduced HAPE incidence by 35%, it did not reduce PA pressure as hypothesized. The non-statistically significant protection against HAPE was considerably less than reductions of >80% with dexamethasone, tadalafil, and nifedipine (along with their associated reductions in PA pressure) in previous studies at the same location. However, the small number of subjects limits a definite conclusion regarding acetazolamide for HAPE prevention, and a larger study is needed. Cellular exposure to extremities leads to the expression of multiple proteins that participate in pathophysiological manifestations. At high altitude (HA), oxidative stresses boost ROS production that may damage the telomeres. Telomeres have long been known as important markers of Aging and cancer, however, the role of telomeres at HA has not been studied so far. Tankyrases (TNKS) belong to multiple telomeric protein complexes and plays protective role during DNA damage, thereby acting as a positive regulator of telomere length. It thus could be an important marker with respect to HA adaptation or maladaptation. The present study investigated the plausible roles of tankyrase SNPs, protein levels and expression profile along with telomere length and telomerase activities with HAPE (high altitude pulmonary edema) in three welldefined groups, namely HAPE-patients (HAPE-p), HAPE-free sojourners (HAPE-r) and healthy highland natives (HLs). Polymorphisms were studied using PCR-RFLP, the protein levels were estimated using ELISA and expression study was carried out using RT-PCR. Tankyrase SNPs, rs7015700G/A, rs12541709& rs11991621 were genotyped. The TNKS heterozygotes rs7015700GA were prevalent in HLs compared to the HAPE-p and HAPE-r. The plasma TNKS was significantly decreased in HAPE-p than HAPE-r (p < 0.01). TNKS was upregulated 9.27 folds in HAPE-p (p < 0.01) and down-regulated in HLs by 3.3 folds (p < 0.05). The telomere length was shorter in HAPE-p compared to HAPE-r (p < 0.05) and HLs (p < 0.01). The telomerase activity was significantly higher in HAPE-p compared to both HAPE-r (p < 0.05) and HLs (p < 0.01). Our findings reveal that tankyrases and telomeres are critical to study adaptation and maladaptation at HA. Right ventricular failure occurs in nearly 50% of patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and may be disproportionate to pulmonary artery pressure; the mechanisms by which RV failure occurs in PH-HFpEF are not known. We previously identified that the natriuretic peptide clearance receptor (NPRC) is the most upregulated gene in the RV of a rodent model of obesity induced PH-HFpEF. In this study, we hypothesized that treatment with an NPRC specific agonist, ANP-4-23, directly contributes to RV failure. Adult, six to eight-week old, AKR mice were treated with ANP-4-23 or saline control for two weeks through an infusion pump, with and without high fat diet. After two weeks, mice underwent echocardiography and direct, open-chest left and right ventricular catheterization. In mice fed low fat diet, treatment with ANP-4-23 led to an increase in RV internal diameter (1.4 AE 0.13 vs. 1.8 AE 0.13 mm, p ¼ 0.003) and decrease in measured RV stroke volume (3.5 AE 0.2 vs. 3.2 AE 0.1 ml, p ¼ 0.03). ANP-4-23 treatment, conversely, led to a decrease in LV internal diameter (3.4 AE 0.05 vs. 3.2 AE 0.1 mm, p ¼ 0.04) with no change in LV stroke volume (4.0 AE 0.2 vs. 4.2 AE 0.5 ml). In the group fed high fat diet, ANP-4-23 led to no statistically significant changes in the RV or LV. High fat diet alone increased RV diameter, decreased RV stroke volume, and increased in RV systolic pressure, but ANP-4-23 treatment had no significant effect in this cohort. In conclusion, an NPRC specific agonist, ANP-4-23, causes selective dilation and decreased contractility of the RV. This effect occurred in the absence of any measured differences in RV systolic pressure, suggesting that NPRC may function to selectively modulate RV function. Pulmonary hypertension upon disease progression leads to heart failure. Previous observations encompass that angiogenesis is severely dysregulated in failing heart, and that targeting of angiogenesis might play a crucial role in maintenance of RV function. Smyd2 is a protein methyltransferase that methylates histones and diverse non-histone proteins. In silico analysis demonstrated the presence of highly conserved Smyd2-specific motif in HIF-1A protein sequence. In this study, we hypothesize that Smyd2-mediated methylation plays a crucial role in HIF-1A stabilization and HIF-1A-mediated angiogenesis. Expression analysis from human right ventricles (RVs) demonstrated that Smyd2 and HIF-1A were upregulated in compensated RVs which was declined in decompensated RVs. A similar expression pattern was observed in pulmonary arterial-banded (PAB) mice. Microarray analysis obtained from Smyd2 overexpression in neonatal rat ventricular cardiomyocytes (NRCMs) showed significant upregulation of pro-angiogenic genes. Hypoxia augmented Smyd2 expression in NRCMs and human cardiac microvascular endothelial cells (HMVECs). Mass spectrometry analysis revealed HIF-1A as a novel substrate of Smyd2 methyltransferase activity, which was further substantiated by utilization of site-specific HIF-1A methylation antibody and HIF-1A methylation-deficient mutant. The interaction between HIF-1A and Smyd2 was studied by immunoprecipitation. Nuclear/cytoplasmic extraction and immunofluorescence staining of cells exposed to hypoxia indicated that Smyd2 exogenous expression leads to HIF-1A stability and HIF-1A nuclear translocation. Smyd2-dependent HIF-1A stabilization was markedly diminished by Smyd2 enzyme-deficient overexpression. Furthermore, Smyd2 deletion reduced hypoxia-induced HIF-1A protein stability both in NRCMs and HMVECs. Cardiomyocyte-specific overexpression of Smyd2 using adeno-associated viral approach (AAV9-CMVIVS-mSmyd2) in PAB mice resulted in a remarkable HIF-1A stabilization, induction of pro-angiogenic markers and improvement of RV function. Our data demonstrates that HIF-1A is a novel substrate of Smyd2 methylation, and Smyd2 mediated proangiogenic signalling has a cardioprotective role in RV hypertrophy.

0022. Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease. Diagnosis of IPAH is performed largely by the exclusion of other forms of PAH resulting in a heterogeneous population of patients with less than 25% attributable to genetics. In order to characterise the heterogeneity, this study applied unsupervised machine learning to whole-blood RNA transcriptomes from a large cohort of 359 patients with idiopathic and heritable PAH. We identified five patient subgroups including three of the largest patient subgroups accounting for 92% of the cohort, each with a unique transcriptomic and clinical feature fingerprint. The three major subgroups were associated with poor (53% five-year survival from sampling), moderate, and good prognosis (78% five-year survival). The poor prognosis subgroup was associated with upregulation of ALAS and downregulation of several immunoglobulin genes, while the good prognosis subgroup showed upregulation of the BMP signalling regulator NOG, and the C/C variant of HLA-DPA1/DPB1 also recently associated with increased survival. We subsequently validated in an independent cohort using clinical signatures associated with the RNA subgroups. These findings provide evidence for the existence of three major subgroups (endophenotypes) of patients within the H/IPAH clinical classification group. The reported clinical and molecular features could improve the current clinical classification, risk stratification, and prognosis prediction as well as offer novel insights into regulators of disease pathogenesis that can be targeted by therapeutics as a precision medicine approach for PAH. Pulmonary arterial hypertension (PAH) is a severe and lifethreatening disease characterized by elevated pulmonary blood pressure. PAH can be categorized into different subgroups, which include idiopathic PAH (IPAH) and PAH associated with other diseases (APAH). While current treatments slow PAH disease progression, they are ultimately not curative. This highlights the need for further investigation of the underlying molecular mechanisms of PAH pathogenesis, to ultimately discover new therapeutic targets. There have been several studies which have transcriptionally profiled and compared control and PAH samples using either gene expression microarrays or RNA-Seq. One challenge is that each of these independent studies analyzed a small number of patient samples, which limits the analytical methods that can be performed. To circumvent this problem, we have pooled multiple publicly available PAH gene expression datasets, which enables us to use more sophisticated computational techniques. While the existing studies focused on studying differential expression at a single-gene level, we leveraged gene set-based computational techniques to study the transcriptional alterations in PAH on a pathway level. We have identified differentially expressed genes and gene signatures between control and PAH samples. Many of them were associated with signalling pathways that have an established role in PAH biology. But interestingly, we were also able to identify new genes and pathways that have not been previously associated with PAH, and thus warrant further experimental validation. This study also compared IPAH with APAH samples with the goal of identifying subtype-specific transcriptional signatures. We also tried to classify all the PAH samples based on their transcriptomic profiles. Excitingly, the samples did not cluster based upon their clinical subtype, but rather into several distinct expression-based clusters, suggesting that PAH patients with different transcriptional profiles may have shared/divergent drug responses. We provided valuable findings for further validation and investigation to develop novel treatments for PAH.

There are limited data on the incidence of chronic thromboembolic pulmonary hypertension (CTEPH). The Sheffield Pulmonary Vascular Disease Unit (SPVDU) serves a population of 15 million. In Sheffield (population 600,000), a pulmonary embolism (PE) follow-up clinic was established in 2010. The study aim was to assess the impact of a PE follow-up clinic on the diagnostic rate and severity of CTEPH. Patients diagnosed with CTEPH (2010-2020) included Sheffield patients referred from the PE clinic (Group1), those not referred through the PE clinic (Group2), and patients with suspected PH referred from outside Sheffield (Group3). CTEPH was defined according to international guidelines and required multimodality imaging, a mean pulmonary artery pressure (mPAP) !25 mmHg at right heart catheterisation, with other causes of PH excluded. Eight hundred and seventy patients were diagnosed with CTEPH. Of 1975 patients evaluated in the PE-follow-up clinic, 35 were diagnosed with CTEPH with a cumulative incidence at two years of 1.5%. There were 77 Sheffield patients with CTEPH (Groups1 and 2) giving a diagnostic rate of 12.8/million/year based on a referral population of 600,000, compared to 5.3/million/year for 790 patients with CTEPH referred from outside Sheffield. Patients from Group 1 had median mPAP 32mmHg (IQR17) and pulmonary vascular resistance (PVR) 287dynes/sec/cm À5 (IQR236), those from Group 2 had mPAP 41 mmHg (IQR14) and PVR 472 mmHg (IQR507) and those from Group 3 had mPAP 46 mmHg (IQR17) and PVR 592 dynes/sec/cm À5 (IQR540), (p < 0.05 for all comparisons, except mPAP Groups 1 vs. 2, p ¼ 0.071 and PVR Groups 2 vs. 3, p ¼ 0.65). In conclusion, the introduction of an acute PE follow-up clinic identifies patients with CTEPH with less severe haemodynamic disease. Integration of such approaches with a national network of PH centres can achieve diagnostic rates for CTEPH of 12.8/million/year. Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of precapillary pulmonary hypertension due to obstruction and vascular remodeling of pulmonary arteries. Treatment of choice is pulmonary endarterectomy (PEA). However, around 40-50% of patients are classified as nonoperable. Alternative treatments for these inoperable cases or for those patients with symptoms and elevated PVR after surgery include pulmonary vasodilators and balloon pulmonary artery angioplasty (BPA). Interestingly, previous works showed a differential treatment for women in comparison to men in this disease, including PEA. The aim of this work was to describe gender-specific differences regarding clinical presentation, haemodynamic profile, management and prognosis in patients with CTEPH in a single referral centre for the study of PH in Spain. Amongst 453 patients evaluated between January 2007 and December 2018, 253 were women (55.9%). Median follow-up time was 50.7 months (interquartile range -IQr -30.0-75.2 months). Mean age was significantly greater in women (61.1 AE 1.0 years vs. 56.2 AE 1.1 years in men; p < 0.001). Regarding treatment, PEA was achieved more frequently on men (123 men vs. 110 women. Absolute difference of þ18.0%; p < 0.001). Nevertheless, there was a trend towards BPA being carried out more usually in women (32 men vs. 55 women, absolute difference of À7.1%; p ¼ 0.065). During follow-up, 15 men and 22 women died. There were no differences in long-term mortality. After multivariate analysis, PEA and BPA were protective factors. On the contrary, diabetes, shorter distance in the six-minute walk test and higher levels of NtproBNP remained as prognostic factors for mortality. In conclusion, this study demonstrates an equivalent longterm survival between both genders, even though women were older and more comorbid at diagnosis. A refined pulmonary artery angioplasty program has probably been more beneficial and effective as a treatment option in female patients. Chronic thromboembolic pulmonary hypertension (CTEPH) is a disease of the pulmonary vasculature characterized by persistent thrombotic occlusion or stenosis of the pulmonary arteries resulting in pulmonary hypertension (PH). Although pulmonary thromboendarterectomy (PTE) remains the treatment of choice for patients with CTEPH, not all patients will benefit from or receive this highly specialized surgery. Patients whose CTEPH is deemed inoperable are candidates for medical therapy, for which only riociguat, a soluble guanylate cyclase stimulator, is FDA approved. Other options include off-label use of therapies for pulmonary arterial hypertension (PAH), a related disease of the pulmonary arterioles. Thus, there is a significant unmet need for novel medical therapies for CTEPH. However, specific cell types that are involved in thrombotic lesions are poorly understood. Here, by using insights from single-cell RNA sequencing (scRNAseq) of CTEPH thrombus, we uncovered distinct populations of immune cells; phenotypically modulated smooth muscle cells (SMCs) and typical cells of the pulmonary vasculature. Cells derived from CTEPH thrombus have defects in angiogenesis and proliferation. We extended our studies by performing GPCR profiling globally, using data from scRNAseq. Global GPCR profiling allowed us to differentiate receptor expression in different cell types in the myofibroblasts, endothelial cells (ECs) and immune cells that compose the thrombus. Over 50 GPCRs targets have been identified in different cell types, in which $20 GPCRs are expressed in SMCs or ECs. Testing a few drug targets in thrombus-derived cells revealed GPCRs, such as the type A endothelin receptor (ETAR) and CXCR3, inhibited the endothelial cells and smooth muscle cells proliferation. These novel findings may enable the design of more precisely tailored CTEPH medical therapies. Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the most severe complications of pulmonary embolism. Aseptic inflammation and fibrous remodeling of the vascular wall are important factors in CTEPH pathogenesis and pharmacological targets to be corrected. The aim of this study was investigating the antifibrotic effect of Janus kinase 1, 2 inhibitor (iJAK) for CTEPH treatment. Wistar rats were used for the experiments. At the first stage, repeated intravenous administration of partially biodegradable microspheres from sodium alginate was performed to embolize the branches of the pulmonary artery and trigger the CTEPH formation. Two weeks after, animals were divided into following groups: low dose (L/D) iJAK -ruxolitinib 0.43 mg/kg twice per day was administered per os during four weeks; middle dose (M/D) iJAK -1.29 mg/kg; high dose (H/D) iJAK -2.14 mg/kg. In Control and Placebo groups, saline was administered in the same regimen. At the end of experiment treadmill test, echocardiography (TTE), right ventricular catheterization with measurement of right ventricular mean pressure (RVMP) and histological examination of the lungs were performed. According to histological examination, the hypertrophy index of vascular wall was significantly higher in all experimental groups compared with the Control (p < 0.01). Moreover, the hypertrophy index was significantly lower in M/D iJAK group compared to Placebo (p ¼ 0.012). According to the treadmill test, exercise tolerance in the M/D iJAK group was higher than in the Placebo group (p < 0.05). There were no significant differences in the level of RVMP between the experimental groups. According to TTE, there was a trend to decrease the fractional shortening of the left ventricle in the (H/D) iJAK group (p ¼ 0.061). In conclusion, using M/D of iJAK in the experimental modeling of CTEPH reduces the severity of pulmonary artery vascular remodeling and increases exercise tolerance. Chronic thromboembolic pulmonary hypertension (CTEPH) is considered to be an extreme variant of pulmonary thromboembolism. Unilateral CTEPH is extremely uncommon. It is not clear if these patients benefit from pulmonary thromboendarterectomy (PTE). Here we report three cases of CTEPH who underwent successful PTE. In this case series, we report three symptomatic patients with CTEPH and CTED patients with unilateral involvements. All the patients underwent pulmonary thromboendarterectomy successfully. There were no other reasons for patient's symptoms. PFT were normal as well. The patients underwent PTE because dyspnea which was otherwise unexplained. First patient was a 37-year-old woman with exertional dyspnea in FC 2. Her VQ scan showed unilateral defect in LLL. Six month after surgery, she was in FC.1. Her 6MWD increased from 328 m to 441 m. Also, m.Pap decreased from 25 mmHg to 19 mmHg. There was no defect in VQ scan six months after the surgery. Second patient was a 30-year-old woman with history of PE and DVT. She had dyspnea in FC 2. VQ scan revealed unilateral segmental defect in LLL. One year after surgery, she was in FC 1. 6MWD improved from 395 m to 474 m without desaturation. Also, her VQ scan test improved completely. The third case was a 30-year-old woman with APS positive. She had history of PE, DVT and CVA. She was symptomatic in FC 2. Her mean Pap at rest was 19 mmHg and after exercise that increased to 32 mmHg. One year after PTE, she was in FC.1. Her 6MWD increase from 260 m to 302 m and mean Pap after exercise decreased from 30 mmHg to 24 mmHg. Although unilateral symptomatic CTEPH is uncommon, but this diagnosis should be considered in evaluation of patients with unexplained shortness of breath, since some of them may get benefit from PTE. Pulmonary arterial hypertension (PAH) is a rare disorder associated with progressive elevation of pulmonary pressures that, if untreated, leads to right heart failure and death. Specific genetic variants increase the incidence of PAH in carriers with idiopathic PAH, hereditary PAH or associated forms. Whole exome sequencing (WES) was carried out in a proband with PAH and primary biliary cirrhosis. A custom pipeline for variant prioritization was carried out to obtain candidate variants and Copy Number Variants (CNVs). To determine the impact of TRAF2 in cell proliferation, we performed an MTS assay on healthy lung pericytes transfected with siRNA specific for TRAF2. To measure the effect of loss of TRAF2 on NF-kappa-beta (NF-jB) activity, we measured levels of Phospho-p65-NF-jB in siRNA-transfected pericytes using western immunoblotting. WES of the proband revealed a de novo protein-truncating variant in the TRAF2 gene and CNV analysis showed a 7703 Mb deletion with an unknown significance at chromosome 4 which encompasses 52 genes, including KDR. TRAF2 encode for immunomodulatory protein that regulate NF-jB activation. The knockdown of TRAF2 increased NF-jB activity in healthy lung pericytes, which correlated with a significant increase in proliferation over 24 h. Loss of function variants in KDR gene has been previously described in PAH individuals associated with interstitial lung disease, but as far as we know, no CNVs that include KDR has been detected so far in patients manifesting PAH. In conclusion, we have identified a rare novel variant in TRAF2 using WES and a 7703 Mb deletion which include KDR gene. We speculate that loss of function in TRAF2 promotes pulmonary vascular remodeling by allowing overactivation of the NF-jB signaling activity; however, the deletion can also play a role in the clinical manifestation of the patient, suggesting a digenic contribution to the PAH phenotype.

Women are more likely to develop pulmonary arterial hypertension (PAH) but exhibit more favorable hemodynamics and increased survival compared to men. These improved outcomes in women have been linked to protective effects of 17ß-estradiol (E2). While the E2 receptor ERa is protective in the systemic vasculature, its function in the cardiopulmonary system has not been explored. Our hypothesis of this study is that loss of ERa exacerbates experimental PH. In vivo studies were performed in male and female ERa mutant or wild-type (WT) littermates with monocrotaline (MCT)-or Sugen/hypoxia (SuHx)-induced PH or pulmonary artery banding (PAB)induced RV failure (PAB-RVF). Hemodynamics, PA and RV remodeling, and molecular changes were assessed. To study effects of E2 or ERa activation, E2 or PPT was utilized in MCT-PH or PAB-RVF using prevention or rescue approaches. p < 0.05 was considered statistically significant. In MCT-PH and SuHx-PH, loss of ERa resulted in more severe disease (demonstrated by increased RV hypertrophy, RV systolic pressure (RVSP), total pulmonary resistance index, as well as decreased cardiac index) compared to WT. This difference in phenotypes was driven by more severe changes in female animals, whereas changes in male ERa mutants were less pronounced. Conversely, treatment with E2 or ERa agonist rescued MCT-PH and PAB-RVF (p < 0.05). In particular, E2 or ERa agonist treatment was associated with less severe MCT-or PAB-induced alterations in RVSP, RV hypertrophy, and RV structure and function and increased survival (p < 0.05). In conclusion, loss of ERa results in more severe PH. E2 treatment or selective ERa activation attenuates PH. These data suggest that ERa exerts protective effects in PH. The more severe phenotype in female ERa mutants with PH suggests that alterations in ERa signaling may contribute to the female bias in PAH. Selectively activating ERa signaling may be a novel strategy to treat PAH and other types of PH. BMPR2 mutation is reported in 80% of familial PAH and 20% of idiopathic cases. Recently, a new rat model of hereditary pulmonary arterial hypertension (HPAH) with a BMPR2 lossof-function mutation has been generated. Similar to humans, only around 20% of the rats spontaneously developed mild HPAH. Unexpectedly, we observed that 20% (95%CI: 12-28) of the 82 Bmpr2 þ/D71 rats (93% of females) versus 4% (95%CI: 0-9) of the 84 age-matched wild-type littermates spontaneously developed mammary masses and ulcerations requiring euthanasia. Interestingly, rats with tumor had elevated PA and exhibit PAH signs. We hypothesized that mammary tumor exacerbates the penetrance of PAH in the BMPR2-mutated female rats. BMPR2-mutated and non-mutated female rats (50 days) were treated with the breast cancer inducer 7, 12-dim ethylbenz(a) anthracene (DMBA) or Vehicle. Five weeks after the treatment, all rats, whatever the genotype, develop mammary tumors. Compare to both vehicle treated and DMBA rats (no tumor), BMPR2-mutated rats with DMBA-induced tumors had a significant increase in mean PA pressure (p < 0.0001); total pulmonary resistance (p < 0.0001) and significant decrease in cardiac output (P ¼ 0.0293). Histologically, these changes were associated with greater amount of pulmonary artery remodelling assessed by EVG coloration. Mechanistically, the development of PAH in the BMPR2 mutated rats with tumor was associated with a significant upregulation of BRD4 (Western blot) (p ¼ 0.0149); IL-1b (p ¼ 0.0052), BRD3 (p ¼ 0.0791) and BIRC5 (p ¼ 0.0166) mRNA expression levels. Co-culture experiments with breast cancer cells and PASMC from both wild-type and BMPR2-mutated animals are ongoing to identify whether cancer cells are realising factors responsible of PASMC proliferation and resistance to apoptosis. We demonstrated for the first time that breast cancer exacerbates PAH development in BMPR2-mutated rats. Increased BRDs-driven pro-inflammatory signaling is associated with PAH development in BMPR2-mutated rats. We are currently exploring whether BMPR2 mutated person are more prone to breast cancer development or not and whether PAH development occur more frequently in breast cancer patients.

Pulmonary arterial hypertension (PAH) manifests by remodeling of small muscular pulmonary arteries (PAs) due to hyperproliferation of pulmonary vascular cells, resulting in maladaptive increase in PA pressure and right ventricle (RV) dysfunction. We previously reported that stiffness-induced deficiency of tuberous sclerosis complex 2 (TSC2) promotes hyper-proliferation and apoptosis resistance of PA vascular smooth muscle cells (PAVSMC) from PAH lungs through YAP/ TAZ-mTOR, and that TSC2 restoration by SRT2104 reduces hyper-proliferation and induces apoptosis in human PAH PAVSMC. The role of TSC2 deficiency in the development of PAH/PH and potential attractiveness of pharmacological restoration of TSC2 remain to be determined. To test the role of VSM-specific Tsc2 deficiency in vivo, we developed mice with VSM-specific heterozygous deletion of Tsc2 (cross-breeding SM22-Cre and Tsc2 flox/flox mice). Nine week-old male SM22-Cre-Tsc2 þ/À mice developed spontaneous PH as evidenced by significantly higher PA medial thickness (PA MT), systolic RV pressure (sRVP) and RV hypertrophy (Fulton Index) compared to same-age controls. To determine effect of pharmacological restoration of Tsc2 on severe experimental PH, we used SU5416/hypoxia rat model. Six to eight-week-old male rats received single dose of SU5416 (20 mg/kg) followed by threeweek exposure to 10% normobaric hypoxia and daily oral treatment with SRT2104 or vehicle under normoxia for next five weeks. We found that SRT2104 restored SMC Tsc2 Despite substantial advancements in the treatment of pulmonary arterial hypertension (PAH), obstacles still remain in achieving the optimal outcomes. Various treatments have been developed to target signaling pathways mostly leading to increased intracellular cAMP. Existence of intracellular cAMP microenvironment and various cAMP regulators and effectors as signalosome, adds a different level of complexity to the cAMP signaling. In vitro studies involved mainly donor and IPAH human pulmonary artery smooth muscle cells (PASMCs). To study the cAMP signalosome complex, we used co-immunoprecipitation, immunofluorescence staining and proximity ligation assay. Functional studies include performing proliferation and apoptosis assay after targeting ADORA1/PDE10A using siRNAs and inhibitors. cAMP levels were measured using ELISA kits. In vivo studies involved treating the SU5416þHypoxia-and MCT-PAH rat models with ADORA1/PDE10A dual inhibitor followed by cardiac MRI, right heart catheterization and lung morphometric analysis. From the expression studies, it was observed that ADORA1 was highly expressed in IPAH PASMCs. However, antiproliferative and pro-apoptotic effects of ADORA1 inhibition was observed only in donor PASMCs, but not in IPAH PASMCs. Further, screening for cAMP inhibiting PDEs (PDE3, PDE4, PDE10A) that can be colocalized with ADORA1, we found that PDE10A was upregulated and was in close proximity to ADORA1 compared to other cAMP-inhibiting PDEs exclusively in IPAH PASMCs compared to donor PASMCs. Importantly, genetic and pharmacological inhibition of both ADORA1 and PDE10A via increased cAMP levels induced both, pro-apoptotic and anti-proliferative effect in human IPAH-PASMCs. Impressively, in in vivo studies, the ADORA1/PDE10A dual inhibitor treatment of SU5416þhypoxia and MCT-PAH rats has shown better survival rate compared to the placebo. The hemodynamics and MRI data have shown that dual inhibitortreated rats were having lower pulmonary vascular resistance, reduced right ventricular hypertrophy and improved cardiac function. The morphometric analysis revealed that the rats treated with dual inhibitor had reduced medial wall thickness and muscularization compared to the placebo group. These results show that targeting ADORA1/PDE10A signalosome regulated cAMP microenvironment is a promising step towards having a better treatment for PAH. 0035. Downregulation of adenylate kinase 4 (AK4) improves the mitochondrial respiration and inhibits the glycolytic switch of pulmonary arterial smooth muscle cells Pulmonary hypertension (PH) is a hypoxia-driven vascular disease characterized by increased proliferation and decreased apoptosis of pulmonary artery smooth muscle cells (PASMCs), and a glycolytic switch similar to the Warburg effect in cancer. The current findings support the concept that the knowledge gained from cancer research may help in the treatment of PH. Adenylate kinase isoenzyme 4 (AK4) is a mitochondrial enzyme that promotes metabolic reprograming and metastasis of lung cancer. In our study, we found that AK4 is up-regulated in human PASMC exposed to hypoxia, in chronic hypoxia mouse model representing group III of PH classification as well as in pulmonary vasculature of patients with idiopathic pulmonary arterial hypertension (IPAH). Under hypoxia, AK4 expression in human PASMC was regulated via hypoxia inducible factor-1a (HIF-1a) and the level of reactive oxygen species (ROS). siRNA-mediated gene silencing experiments showed that AK4 downregulation decreases the phosphorylation of protein kinase B (AKT) which is a critical regulator of cell survival and growth. We could show that AK4 silencing increased the apoptosis of PASMC via elevating the level of a pro-apoptotic protein Bax. Furthermore, AK4 downregulation inhibited a glycolytic switch of hypoxic PASMC by decreasing the level of hexokinase II, lactate dehydrogenase and pyruvate dehydrogenase kinase. Consequently, the AK4 depletion improved the mitochondrial respiratory function of PASMC both under normoxic and hypoxia-mimicking conditions. We conclude that AK4 is involved in the regulation of the Warburg effect and mitochondrial function of human pulmonary artery smooth muscle cells indicating its therapeutic potential in the treatment of pulmonary hypertension. We acknowledge the support of the European Respiratory Society, and the "Deutsches Zentrum für Lungenforschung" (Fellowship LTRF 2018).

Pulmonary hypertension (PH) has been described in patients treated with leflunomide. The objective of this study was to assess the association between leflunomide and PH. We identified incident cases of PH in patients treated with leflunomide from the French PH registry and through the VIGIAPATH pharmacovigilance program between September 1999 and December 2019. PH aetiology, clinical, functional, radiologic, and haemodynamic characteristics were reviewed at baseline and follow-up. A pharmacovigilance disproportionality analysis using the World Health Organization's (WHO) global database was conducted. We then investigated the effect of leflunomide on human pulmonary endothelial cells (h-PECs). Data are expressed as median (min-max). Twenty-eight patients treated with leflunomide before PH diagnosis were identified. Twentythree (75%) had another risk factor for PH and two had two risk factors. The median time between leflunomide initiation and PH diagnosis was 32 months . Right heart catheterisation confirmed precapillary PH with a cardiac index of 2.37 L. min À1 .m À2 (1.19-3.1) and elevated pulmonary vascular resistance at 9.63 Wood Units (3.6-22.1) without nitric oxide reversibility. Five patients (17.9%) had no other risk factor for PH besides exposure to leflunomide. No significant hemodynamic improvement was observed after leflunomide withdrawal. The pharmacovigilance disproportionality analysis using the WHO database revealed a significant overrepresentation of leflunomide among reported PAH adverse drug reactions. In vitro studies showed dose-dependent toxicity of leflunomide on h-PECs. In conclusion, PH associated with leflunomide is rare and usually associated with other risk factors. The pharmacovigilance analysis suggests an association reinforced by experimental data.

Youlan Rao, Lisa Edwards, Dana Johnson and C.Q. Deng United Therapeutics Corp, Durham, NC, USA An addendum to ICH Efficacy Guideline E9 (Statistical Principles for Clinical Trials) was finalized and released in November 2019. The addendum introduced the concept of estimands to ensure alignment of the objectives of a clinical trial with its design, conduct, and analysis. The estimand framework is defined by five inter-related attributes: the treatment condition of interest, the population of interest, the variable (endpoint) to be obtained, the way intercurrent events are handled, and the population level summary for the variable. We discuss how the estimand framework and the five estimand attributes may be applied to the common designs (measurement at fixed time point or longitudinal measurement with fixed duration and event-driven study) in PAH clinical trials. We illustrate how the estimand framework can bring more alignment, clarity, and transparency to commonly used endpoints such as time to clinical worsening events, change in functional capacity measures (such as 6MWD, Peak VO 2 ) from baseline to a fixed, post-baseline assessment, and hemodynamic measures (such as PVR). The common intercurrent events (such as early discontinuation of the study drug and change in background PAH therapies) in PAH studies and the strategies to handle them will also be discussed. We conclude with recommendations for incorporating estimand framework when planning future PAH clinical trials, hoping that this will drive further development of a common framework based on the addendum that can be applied to protocols, statistical analysis plans, and clinical study reports in the future.

0038. Risk stratification in pulmonary hypertension due to chronic obstructive pulmonary disease Pulmonary hypertension (PH) is common in patients with chronic obstructive pulmonary disease (COPD) and treatment decisions should be goal orientated. Recently, differentiation into COPD with PH and COPD with severe PH based on mean pulmonary arterial pressure, pulmonary vascular resistance and cardiac index was proposed. The ESC/ERS risk stratification scheme has been shown to be predictive in patients with restrictive lung diseases. It is, however, unclear how to assess risk in patients with COPD-PH. Incident patients with COPD-PH who were enrolled between 1995 and 2018 in the Giessen PH Registry were included. Risk stratification was performed either by classification into severe and non-severe COPD-PH as proposed by Nathan and coworkers or by a truncated version of the ESC/ERS risk stratification scheme as previously described by us. Kaplan-Meier analyses and Cox-regression analyses were utilized to evaluate mortality. Two hundred and seventy-four incident patients with COPD-PH were included (38% female, median 70 [65; 78] years). Prevalence of severe COPD-PH was 47%. Patients with severe COPD-PH showed slightly increased mortality rates (five-year survival: 51% vs. 43%, log-rank p ¼ 0.143). ESC/ERS risk stratification did not predict mortality in patients with COPD-PH (log-rank p ¼ 0.163) and in a subgroup of patients with severe COPD-PH (log-rank p: 0.574). Univariate Coxregression revealed that mPAP, PVR, 6MWD, FVC (% pred) and TAPSE/PASP ratio predict mortality. Stepwise backward Cox-regression showed that solely 6MWD and TAPSE/PASP ratio are independently associated with mortality. A scoring system based on these parameters accurately predicts mortality (Cut-offs: 299 m and 0.35 mm/mmHg, Youden's index). Fiveyear survival of patients with both, one and no parameter above thresholds was 87%, 62% and 27%, respectively (logrank p < 0.001). In conclusion, risk stratification based on 6MWD and TAPSE/PASP ratio as a surrogate marker for right ventricular pulmonary arterial coupling precisely predicts mortality in patients with COPD-PH, whereas commonly used risk scores are not appropriate.

0039. Small pulmonary vessels in severe pulmonary hypertension associated with chronic lung disease Pulmonary hypertension (PH) in patients with chronic lung disease (CLD) is associated with reduced functional status and high mortality. The morphological changes of pulmonary blood vessels in patients with PH associated with CLD is incompletely understood. The aim of this study was to assess the association between computed tomography (CT)-derived quantitative pulmonary vessel parameters and PH severity in CLD. Patients with CLD who underwent baseline CT pulmonary angiography, pulmonary function tests (PFTs) and right heart catheterisation were identified between October 2012 and July 2018. Quantitative assessments of total pulmonary vessel, small pulmonary vessel (vessel diameters < 0.8/1.2/ 1.6 mm) and peel pulmonary vessel volumes (outer 15/30/ 45 mm) were performed. One hundred and sixty-eight patients were identified. Thirty-one had no PH and no lung disease on CT or PFTs, 54 patients had COPD/emphysema, 54 patients had interstitial lung disease (ILD) and 29 patients had combined pulmonary fibrosis emphysema (CPFE) syndrome. Patients with ILD had lower total, small and peel pulmonary blood vessel volumes, compared to other groups but higher with COPD/ emphysema than other groups (p < 0.05). Mean pulmonary artery pressure (mPAP) was negatively associated with the volume of small pulmonary vessels < 0.8 mm, < 1.2 mm and < 1.6 mm in diameter in patients with COPD/emphysema. In patients with ILD, a stronger correlation was identified between mPAP and pulmonary vascular resistance with pulmonary vessel volumes < 0.8 mm, < 1.2 mm and < 1.6 mm and also with lung volume. Patients with COPD/emphysema and ILD who had mean pulmonary artery pressure >35 mmHg, had lower small pulmonary vessel volume. Higher mortality was identified in patients with lower small vessel volumes (Log-rank 6.7, p ¼ 0.01). In conclusion, lower small pulmonary vessel volume is associated with severe PH in COPD/emphysema and ILD. CT pulmonary vessel analysis may provide a quantitative measure of small pulmonary vessel remodelling in PH associated with CLD. 0040. A phase 1, open-label, crossover study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects Jack Li 1 , Matt Cravets 1 , Emanuel DeNoia 2 , Debbie Slee 1 and Larry Zisman 1 1 Gossamer Bio, Inc., San Diego, CA, USA; 2 ICON Clinical Research, LLC, Gaithersburg, MD, USA Seralutinib (also known as GB002) is an inhaled, small molecule kinase inhibitor specifically developed for the treatment of pulmonary arterial hypertension (PAH), with an optimized kinase specificity profile that targets PDGFRa/b, cKIT, and CSF1R and modulates BMPR2. Targeting these pathways may reverse pulmonary vascular inflammation, cellular proliferation, and fibrosis. In addition, by directly targeting the diseased lung, inhaled seralutinib limits systemic exposure. Based on in vitro predictions and given that multi-agent regimens are often required in treating PAH, we evaluated the potential for drug-drug interactions (DDIs) with inhaled seralutinib. Twenty-four healthy adults received a cocktail of probe substrates: caffeine (CYP1A2), montelukast (CYP2C8), flurbiprofen (CYP2C9), midazolam (CYP3A), digoxin (P-gp) and pravastatin (OATP1B1/1B3) with or without seralutinib. PK and safety were evaluated. Geometric least square mean ratios for C max and AUC of probe substrates with/without seralutinib are shown. Seralutinib is a moderate CYP3A inhibitor per the effect on midazolam. Based on the moderate effect, seralutinib is not expected to cause clinically relevant DDIs with most PAH drugs that are CYP3A substrates (tadalafil, riociguat, bosentan, macitentan); these drugs may be co-administered without dose modification. In the case of sildenafil, dose adjustments should be considered based on risk-benefit assessment. In addition, clinically relevant DDIs with substrates of CYP1A2, CYP2C8, CYP2C9, CYP2C19, P-gp, or OATP1B1/1B3 are not anticipated. Seralutinib was well tolerated with or without co-administered agents.

The distinction between pre-capillary and post-capillary pulmonary hypertension (PH) has important implications for treatment. However, this distinction remains challenging, especially in non-referral centres where the access to right heart catheterization (RHC) may be limited and pre-capillary PH is rarely seen. It is currently unknown how clinicians in non-referral centres deal with the diagnostic challenge in PH and what factors determine their clinical decision making when to perform a RHC. Understanding clinical decision making is essential to diminish the diagnostic delay in PH. Therefore, we aimed to determine which patient characteristics and echocardiographic parameters play a role in the decision to perform a RHC for the diagnostic work-up of incident PH patients seen in nonreferral centres. The Dutch OPTICS registry was used to determine the clinical characteristics of incident PH patients seen in 13 non-referral centres. Clinical data included patient demographics, medical history, NT-proBNP and echocardiography parameters. A total of 275 patients were included in the analysis with a mean age of 71 AE 12 years. One hundred and fifty-seven patients underwent a RHC (34 chronic thromboembolic PH, 38 PAH, 81 post-capillary PH, four miscellaneous PH) and 118 patients were labelled as post-capillary PH without hemodynamic confirmation. As expected, absence of diastolic dysfunction, right atrial dilation and moderate to severe PH (tricuspid regurgitation velocity >3.7 m/s) were associated with a positive decision to perform a RHC. However, on top of these factors, older age (>73 years) was independently associated with the decision not to perform a RHC. In conclusion, older age is one of the main reasons not to perform a RHC in the diagnostic work-up of PH in non-referral centres. As such, RHC might be underused in the elderly, which could cause underdiagnoses of treatable pre-capillary PH in these patients. Like cancer, pulmonary arterial hypertension (PAH) is characterized by exaggerated proliferation and resistance to apoptosis related to metabolic alterations of pulmonary smooth muscle cells (PASMCs). These anomalies result in a progressive narrowing of the pulmonary arteries, increasing pulmonary resistance and leading to right heart failure and premature death. In cancer cells, unphosphorylated and nuclear FOXO3 has been extensively studied as a crucial protein that functions as a tumor suppressor by regulating expression of genes involved in apoptosis and cell cycle arrest. These functions combined with other FOXO3 attributes, including its key role in communicating mitochondrial-nuclear signals, make the FOXO3 a suitable candidate for controlling the cancer-like phenotype of PAH-PASMCs. Interestingly, AKT and AMPK known to be implicated in PAH exert antagonistic effects on FOXO3; AKT promoting its nuclear exclusion while AMPK favors its nuclear and mitochondrial accumulation. We hypothesize that FOXO3's nuclear exclusion (secondary to AKT/AMPK imbalance) promotes metabolic reprogramming towards glycolysis leading to enhanced proliferation/resistance to apoptosis of PAH-PASMCs and vascular remodeling. Using Western blot and immunofluorescence in isolated PASMCs from both PAH and control patients, we found that nuclear (and mitochondrial) exclusion of FOXO3 due to its phosphorylation is a feature of PAH-PASMCs. In vitro, we demonstrated that pharmacological activation (nuclear localization) of FOXO3 using an adenovirus expressing a constitutively active, non-phosphorylable form of FOXO3 or trifluoperazine resulted in reduced PAH-PASMC proliferation and resistance to apoptosis. These effects were accompanied by increased expression of P27 and SOD2 and diminished expression of Survivin. In vivo, we showed that FOXO3 activation using TPF improved established PAH in the monocrotaline rats (reduced RVSP and increased Sv and CO, by right catheterization) without any sign of toxicity. We showed that FOXO3 is implicated in pulmonary vascular remodeling. Pharmacological activation of FOXO3 may represent a novel avenue to improve PAH. 0044. Non-invasive surrogate markers of PH are associated with poor survival in lung cancer patients 0046. Improving guidance for the correctability of congenital cardiovascular shunts with increased pulmonary vascular resistance Ronald W. Day Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City, UT, USA Based upon expert opinion, guidelines have been proposed for the correctability of congenital cardiovascular shunts with increased pulmonary vascular resistance. This study reports the accuracy of published guidelines using a dataset from the Inhaled Nitric Oxide as a Preoperative Test study. The hemodynamic measurements and outcome of 71 patients with relatively high pulmonary vascular resistance who underwent corrective surgery or heart transplantation were used to determine how well recent guidelines would accurately identify correctable and uncorrectable patients. The accuracy of preoperative testing was 18%, 30% and 17% using a baseline indexed pulmonary vascular resistance less than 4 units-m 2 , indexed pulmonary vascular resistance less than 6 units-m 2 and ratio of pulmonary to systemic vascular indices less than 0.30 as criteria for correctable shunts, respectively. Accuracy improved to 59%, 82% and 85% by using the results of acute vasodilator testing with oxygen and nitric oxide instead of baseline measurements. The accuracy of preoperative testing was 49% and 55% using a baseline indexed pulmonary vascular resistance greater than 8 units-m 2 and a ratio of pulmonary to systemic vascular indices greater than 0.50 as criteria for uncorrectable shunts, respectively. Accuracy improved to 87% and 89% by using the results of acute vasodilator testing with oxygen and nitric oxide instead of baseline measurements. Some patients would be inappropriately cleared for correction and subsequently experience a poor outcome by using the results of vasodilator testing instead of baseline measurements. However, a substantially greater proportion of patients would be appropriately cleared for correction and have a good outcome. In conclusion, guidelines using baseline hemodynamic measurements do not provide accurate guidance for identifying patients with correctable or uncorrectable congenital cardiovascular shunts and increased pulmonary vascular resistance. The accuracy of a preoperative evaluation can be increased with acute vasodilator testing.

Wouter Jacobs 3 , Hans P. Grotjohan 4 , Marc Waskowsky 4 , Jan van der Maten 5 , Arno van der Weerdt 5 , Romke Hoekstra 6

The Hague; 8 Hospital group Twente, Almelo; 9 Spaarne Gasthuis, Haarlem; 10 Catharina hospital, Eindhoven; 11 Jeroen Bosch hospital's

Retrospective cohort of infants born at <29 weeks' gestational age, admitted between 2015 and 2019 and without genetic or congenital anomalies. Measurements from the echocardiography acquired closest to 36 weeks PMA were done by masked experts. PH was considered significant when estimated systolic pulmonary pressure (SPAP) was >2/3 of systemic systolic blood pressure. A total of 222 infants were included, 24 (11%) categorized as significant PH. PH was associated with increased eccentricity index (1.31 AE 0.21 vs. 1.17 AE 0.19, p ¼ 0.002), decreased tricuspid annular plane systolic excursion

The European Society of Cardiology/European Respiratory Society (ESC/ERS) Guidelines specify right atrial thresholds for both echocardiography and cardiac magnetic resonance imaging (cMRI), to aid risk stratification of patients with pulmonary atrial hypertension (PAH), as part of a multi-parameter risk assessment. The aim of this study was to evaluate these thresholds for risk stratification using cMRI. Consecutive incident, treatment-naïve patients with PAH who underwent cMRI, were identified between July 2007 and March 2017 from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry. Data for one-year mortality using ESC/ERS cMRI right atrial area thresholds were assessed at diagnosis and follow-up. A total of 444 patients met the inclusion criteria and 179 underwent a further cMRI after a minimum of three months following initiation of treatment. There were 214 deaths during follow-up. Figure 1 shows the one-year survival of patients with PAH according to ESC/ ERS risk thresholds for minimum and maximum right atrial area. Figure 2 shows the Kaplan-Meier survival curves. In conclusion, using cMRI, current ESC/ERS right atrial area thresholds can be used to identify patients at high-risk of one-year mortality but do not identify patients at low risk.Pulmonary Circulation Volume 11 Number 4 | 21

Pulmonary arterial hypertension (PAH) is a lethal pulmonary arterial vasculopathy that results in right ventricular dysfunction (RVD). We previously showed that microtubule-mediated junctophilin-2 (MT-JPH2 pathway) downregulation promotes ttubule disruption and RVD, but the upstream regulators of this pathway are unknown. Glycoprotein 130 (GP130) signaling via its downstream mediator, signal transducer and activator of transcription 3 (STAT3) promotes microtubule remodeling in cardiomyocytes. However, the relationship between GP130 signaling and the MT-JPH2 pathway in RVD is unknown. We tested the hypothesis that antagonism of GP130 signaling improves RV function by normalizing the MT-JPH2 pathway. Immunoblots of RV extracts quantified levels of GP130 and the MT-JPH2 pathways. Quantitative mass spectrometry analyzed the microtubule-associated protein fraction of RV extracts. Metabolomics defined the RV metabolic signature. Echocardiography, pressure-volume loops, and pulmonary vascular histology assessed RV function and pulmonary vascular disease severity. Finally, we examined the relationship between the GP130 agonist, IL-6 and RVD in PAH patients. GP130 antagonism with SC144 blunted RV STAT3 activation, normalized the MT-JPH2 pathway, and restored t-tubule architecture. SC144 restored the expression of 2842 proteins in the microtubuleassociated protein fraction as determined by mass spectrometry, with significant changes in the expression of mitochondrial proteins. Metabolomic profiling revealed an improvement in RV metabolism in SC144 RVs. Finally, SC144 enhanced RV function (TAPSE 2.4 AE 0.2 vs. 1.9 AE 0.1 mm, p ¼ 0.004), augmented RVpulmonary artery coupling (Ees/Ea 0.9 AE 0.1 vs. 0.4 AE 0.1, p ¼ 0.002), blunted RV hypertrophy, and improved survival (100 vs. 70%) compared to vehicle without altering pulmonary vascular disease severity. In PAH patients, higher IL-6 levels were associated with higher NT-proBNP levels and lower RV fractional area change despite no differences in pulmonary vascular disease burden. In conclusion, inhibition of GP130 improves RV function and survival in monocrotaline PAH via modulation of microtubules. Disclosures: KWP receives modest consultation fees from Actelion and grant funding from United Therapeutics.TT receives modest consultation fees from Actelion and Gilead. The other authors have declared that no conflict of interest exists.

Approximately 60%-70% of patients with lung cancer have dyspnea at presentation, and 90% experience it just prior to death. Considering case reports describing the formation of pulmonary hypertension (PH) via pulmonary tumor microemboli from gastric and gallbladder cancer. To investigate the impact of PH in lung cancer, we retrospectively analyzed measurements of pulmonary artery (PA) and ascending aorta (A) diameter from pre-treatment images acquired with high-resolution computed tomography scans. These data revealed that 293 of 670 (43.7%) lung cancer patients had a mean PA size of !28 mm, indicating PH. Notably as a stronger surrogate parameter for PH, 151 of 670 patients (22.5%) had a PA/A ratio>1. In addition, we calculated the echo pulmonary artery systolic pressure (ePASP) of 132 patients in whom echocardiographic data were available. The mean ePASP in the PA/A ratio >1 group was 38.6 AE 13.1 mmHg, compared to 28.5 AE 7.5 mmHg for PA/A ratio 1. These changes were not accompanied by indicators of right ventricular failure and left heart function was also not significantly different in both groups. Next, to investigate the impact of PH on the survival of lung cancer patients, we evaluated the progression-free survival (PFS) and overall survival (OS) using an adjusted Cox PH regression analysis. Importantly, the median PFS was significantly shorter in patients with lung cancer and PH when a cutoff PA size of !28mm was used (median PFS PA < 28 mm ¼ 257 days; median PFS PA !28 mm ¼ 197 days), and the difference was even more prominent, when a cut-off PA/A ratio of >1 was employed (median PFS PA/A ratio 1 ¼ 270 days; median PFS PA/A ratio >1 ¼ 133 days). Median OS was also significantly reduced for patients with PA size !28 mm (375 days vs. 583 days) and PA/A ratio >1 (207 days vs. 568 days). Thus, a decrease in median OS of one year suggests a marked impact of PH on survival of lung cancer patients. In summary, our study confirms the previous finding that PH is present in a significant proportion of lung cancer patients. Moreover, this is the first report to show that the presence of PH has marked impact on the clinical outcome of lung cancer patients including survival. 0045. The impact of chronic pulmonary hypertension on ventricular function in extremely premature infants